Hypothesis
Senescent cells exhibit a spectrum of SASP profiles that are shaped not only by the senescence trigger but also by the metabolic state of the cell. Recent work shows CD36 is rapidly upregulated upon senescence and initiates NF‑κB‑dependent cytokine production via amyloid‑beta signaling [2]. Parallel data indicate that mitochondrial dysfunction—low NAD+/NADH, reduced SIRT3/SIRT5, and Complex I impairment—amplifies SASP by suppressing AMPK and activating mTOR [3]. The SenNet consortium has further demonstrated that these mechanisms operate differently across tissues, producing context‑dependent SASP signatures [1).
Core proposition: In a given tissue, CD36‑mediated amyloid‑beta signaling acts as a molecular switch that determines whether the SASP skews toward a pathological, chronic inflammatory phenotype or a transient, repair‑supportive phenotype. This switch is modulated by the intracellular NAD+/SIRT3 axis; boosting NAD+ and SIRT3 activity flips the switch toward the reparative SASP without abolishing CD36 signaling entirely.
Mechanistic reasoning
- CD36 as a scaffold for amyloid‑beta‑dependent NF‑κB activation – Amyloid‑beta binds CD36, triggering a Src‑family kinase cascade that sustains IKK activity. This pathway is fast‑acting and drives early SASP cytokines (IL‑6, IL‑8, CCL2).
- NAD+/SIRT3 modulates the kinase scaffold – SIRT3 deacetylates and inhibits Src family kinases (e.g., Fyn) an





























